Multicenter retro-prospective observational study on chronic hypoparathyroidism and rhPTH (1-84) treatment

Area of Science:

• Endocrinology
• Metabolic Bone Diseases

Background:

• Hypoparathyroidism is a rare endocrine disorder characterized by insufficient parathyroid hormone production.
• Conventional treatment for hypoparathyroidism involves calcium and vitamin D supplementation, which can be difficult to manage and may lead to complications.

Purpose of the Study:

• To evaluate the efficacy and safety of 12-month recombinant human parathyroid hormone (1-84) [rhPTH (1-84)] treatment in hypoparathyroid patients.
• To assess the impact of rhPTH (1-84) on biochemical parameters, renal function, and clinical manifestations.

Main Methods:

• A multicenter, observational, retro-prospective, open-label study involving 14 adult hypoparathyroid patients.
• Treatment with rhPTH (1-84) for 12 months.
• Monitoring of serum and urinary calcium and phosphate, calcium-phosphate product, renal function, and clinical symptoms.

Main Results:

• rhPTH (1-84) treatment normalized serum calcium levels within 12 months, with 61.5% discontinuing calcium and 69.2% discontinuing calcitriol.
• Mean phosphatemia levels decreased significantly over the 12-month treatment period.
• Renal function remained stable, and no severe adverse events were reported.

Conclusions:

• rhPTH (1-84) therapy is effective and safe for managing hypoparathyroidism.
• This hormonal replacement therapy offers a valuable alternative for patients not adequately controlled by conventional treatments.